Congratulatory remarks [0.03%]
致欢迎词
June Sung Lee
June Sung Lee
Impact of the 2024 medical-policy conflict on hepatocellular carcinoma management in Korea [0.03%]
2024年医疗政策冲突对韩国肝细胞癌管理的影响
Soon Sun Kim,Hyun Yang,Jieun Kwon et al.
Soon Sun Kim et al.
In 2024, a nationwide conflict between the South Korean government and the medical community, the medical-policy conflict, profoundly impacted healthcare delivery. This study aimed to evaluate the changes in the management of hepatocellular...
Association between metabolites and hepatocellular carcinoma: findings from a two-sample Mendelian randomization study [0.03%]
基于孟德尔随机化研究的代谢产物与肝细胞癌关系分析
Tung Hoang,Van Mai Truong,Tho Thi Anh Tran et al.
Tung Hoang et al.
Background: Identifying metabolic biomarkers can enhance early detection and risk stratification of hepatocellular carcinoma (HCC). We conducted a two-sample Mendelian randomization (MR) study to assess the potential caus...
Current status and future perspectives of minimally invasive liver surgery for hepatocellular carcinoma [0.03%]
肝细胞癌微创肝脏手术的现状和未来展望
Jai Young Cho,Ho-Seong Han,Yoo-Seok Yoon et al.
Jai Young Cho et al.
The use of laparoscopic liver resection has rapidly increased. According to two international consensus meetings, certain resection methods are already considered standard procedures for liver resection, especially for small malignant tumor...
Navigating Liver Cancer with Mouse Models: A Comprehensive Overview of HCC Experimental Systems [0.03%]
利用小鼠模型导航肝癌：HCC实验系统的全面概述
Ga-Young Kim,Dokyung Kim,Jaehyun Jeon et al.
Ga-Young Kim et al.
Hepatocellular carcinoma (HCC) is the most prevalent primary hepatic malignancy and is globally the third leading cause of cancer-related deaths. Despite significant advancements in diagnostic techniques and therapeutic interventions, HCC p...
Preventing False Positive Imaging Diagnosis of HCC: Differentiating HCC from Mimickers and Practical Strategies [0.03%]
防止误诊为肝细胞癌的影像学策略及鉴别要点
Ijin Joo
Ijin Joo
Noninvasive imaging-based diagnosis of hepatocellular carcinoma (HCC) in high-risk patients plays a central role in clinical practice. Current major guidelines typically rely on the radiologic hallmark of nonrim arterial phase hyperenhancem...
Public Health Strategies for Hepatocellular Carcinoma: From Risk Factors to Prevention and Control [0.03%]
肝细胞癌的公共卫生策略——从危险因素到预防和控制措施
Mei-Hsuan Lee
Mei-Hsuan Lee
Hepatocellular carcinoma (HCC) remains a major global health burden, ranking as one of the leading causes of cancer-related deaths worldwide. This review synthesizes current evidence on HCC epidemiology, highlighting both modifiable and non...
Expert survey on systemic therapy indications for hepatocellular carcinoma in Korea: bridging clinical practice and reimbursement criteria [0.03%]
韩国肝细胞癌系统治疗适应症专家调查：连接临床实践和报销标准
Hyun Yang,Soon Sun Kim,Seong Hee Kang et al.
Hyun Yang et al.
This survey aimed to collect expert opinions from multidisciplinary specialists involved in the management of hepatocellular carcinoma (HCC) in Korea regarding real-world criteria for systemic therapy indications. In response to discrepanci...
Jiwon Yang,Gunho Kim,Ju Hyun Shim et al.
Jiwon Yang et al.
Diabetes mellitus (DM) is a cardiometabolic risk factor associated with the development of various comorbidities and malignancies. It has a bidirectional relationship with chronic liver disease, promoting hepatic inflammation and fibrosis, ...
Evolving roles of systemic therapy in hepatocellular carcinoma: neoadjuvant and adjuvant strategies [0.03%]
肝细胞癌系统治疗的 evolving roles：新辅助和辅助策略
Ho Soo Chun,Minjong Lee,Tae Hun Kim
Ho Soo Chun
Surgical resection for early-stage hepatocellular carcinoma (HCC) provides the potential for long-term survival but recurrence rates within 5 years were up to 70%. Thus, neoadjuvant or adjuvant strategies can be important to improve outcome...